Beta Bionics, Inc.(BBNX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BBNX Beta Bionics, Inc.

盘前交易 01-14 06:46:50 EST

17.27

-0.38

-2.15%

最高17.65	最低16.02	成交量220.83万
今开17.51	昨收17.65	日振幅9.26%
总市值7.60亿	流通市值4.09亿	总股本4,402万
成交额3,765万	换手率9.32%	流通股本2,370万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BBNX","market":"US","secType":"STK","nameCN":"Beta Bionics, Inc.","latestPrice":17.27,"timestamp":1768338000000,"preClose":17.65,"halted":0,"volume":2208268,"delay":0,"floatShares":23702000,"shares":44024631,"eps":-1.769,"marketStatus":"盘前交易","change":-0.38,"latestTime":"01-14 06:46:50 EST","open":17.51,"high":17.65,"low":16.015,"amount":37651059.938988,"amplitude":0.092635,"askPrice":19.2,"askSize":100,"bidPrice":16,"bidSize":29,"shortable":3,"etf":0,"ttmEps":-1.769,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768401000000},"marketStatusCode":1,"adr":0,"listingDate":1738213200000,"exchange":"NASDAQ","adjPreClose":17.27,"postHourTrading":{"tag":"盘后","latestPrice":17.26,"preClose":17.27,"latestTime":"19:41 EST","volume":340619,"amount":5882449.414,"timestamp":1768351291338},"volumeRatio":0.8201612772777218,"impliedVol":0.9654,"impliedVolPercentile":0.7857},"requestUrl":"/m/hq/s/BBNX","defaultTab":"news","newsList":[{"id":"2583183505","title":"Beta Bionics, Inc.盘中异动 下午盘急速下跌5.01%报26.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583183505","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583183505?lang=zh_cn&edition=full","pubTime":"2025-11-14 02:17","pubTimestamp":1763057853,"startTime":"0","endTime":"0","summary":"北京时间2025年11月14日02时17分，Beta Bionics, Inc.股票出现波动，股价急速跳水5.01%。截至发稿，该股报26.75美元/股，成交量18.1097万股，换手率0.41%，振幅8.43%。Beta Bionics, Inc.股票所在的医疗器械行业中，整体涨幅为0.56%。Beta Bionics, Inc.公司简介：Beta Bionics Inc 是一家商业化阶段的医疗器械公司，致力于设计、开发和商业化解决方案，通过利用自适应闭环算法简化和改善其疾病治疗，改善需要胰岛素的糖尿病患者  的健康和生活质量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114021733a6f798eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114021733a6f798eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","BBNX"],"gpt_icon":0},{"id":"1115917472","title":"异动解读 | 贝塔生物电子股价盘中大涨19.07%，分析师上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1115917472","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115917472?lang=zh_cn&edition=full","pubTime":"2025-10-29 22:41","pubTimestamp":1761748867,"startTime":"0","endTime":"0","summary":"周三盘中，贝塔生物电子（Beta Bionics，股票代码：BBNX）股价大涨19.07%，引起投资者广泛关注。\n\n消息面上，华尔街知名投资银行Leerink Partners对贝塔生物电子的前景看好，将该公司的目标股价从28美元上调至33美元。这一利好消息被认为是推动公司股价大幅上涨的主要原因。\n\n分析人士认为，Leerink Partners上调目标价反映了对贝塔生物电子未来发展的积极预期。这可能与公司在人工智能辅助糖尿病管理系统方面的创新和市场潜力有关。然而，投资者仍需密切关注公司未来的财务表现和产品开发进展，以评估这一股价上涨是否具有持续性。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BBNX"],"gpt_icon":0},{"id":"1153684762","title":"异动解读 | 贝塔生物电子股价盘前大涨14.87%，Leerink Partners上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1153684762","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153684762?lang=zh_cn&edition=full","pubTime":"2025-10-29 16:18","pubTimestamp":1761725922,"startTime":"0","endTime":"0","summary":"周三盘前，贝塔生物电子（Beta Bionics，股票代码：BBNX）股价大涨14.87%，引起投资者广泛关注。\n\n消息面上，华尔街知名投资银行Leerink Partners对贝塔生物电子的前景看好，将该公司的目标股价从28美元上调至33美元。这一利好消息可能是推动公司股价大幅上涨的主要原因。\n\n分析人士认为，Leerink Partners上调目标价反映了对贝塔生物电子未来发展的积极预期。这可能与公司在人工智能辅助糖尿病管理系统方面的创新和市场潜力有关。然而，投资者仍需密切关注公司未来的财务表现和产品开发进展，以评估这一股价上涨是否具有持续性。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BBNX"],"gpt_icon":0},{"id":"2578269479","title":"Beta Bionics旗下输注器械类产品获FDA批准，注册证号为K252770","url":"https://stock-news.laohu8.com/highlight/detail?id=2578269479","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578269479?lang=zh_cn&edition=full","pubTime":"2025-10-27 10:01","pubTimestamp":1761530460,"startTime":"0","endTime":"0","summary":"产品名称：iLet ACE Pump，所属单位：Beta Bionics，产品类型：输注器械，产品详情：iLet ACE Pump是一款具备备用控制器功能的胰岛素泵，适用于 6 岁及以上糖尿病患者。iLet ACE Pump配备图形用户界面和警报功能，可实现与 iLet 输注系统及 iAGC 的交互操作。iLet ACE Pump搭载电机传动式输注机构，可独立驱动胰岛素从 “单独装入泵体的药筒” 中输出。审批机构：FDA，证件类型：二类，注册证编号：K252770，获批时间：2025-09-29","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510271008369743cf1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510271008369743cf1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBNX","BK4082"],"gpt_icon":0},{"id":"2556846826","title":"Beta Bionics, Inc.2025财年第二财季实现净利润-16.87百万美元，同比减少16.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556846826","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556846826?lang=zh_cn&edition=full","pubTime":"2025-08-03 00:01","pubTimestamp":1754150479,"startTime":"0","endTime":"0","summary":"8月3日，Beta Bionics, Inc.公布财报，公告显示公司2025财年第二财季净利润为-16.87百万美元，同比减少16.67%；其中营业收入为23.24百万美元，同比增加54.42%，每股基本收益为-0.39美元。从资产负债表来看，Beta Bionics, Inc.总负债28.34百万美元，其中短期债务1.52百万美元，资产负债比为0.12，流动比率为0.15。机构评级：截至2025年8月3日，当前有9家机构对Beta Bionics, Inc.目标价做出预测，其中目标均价为23.67美元，其中最低目标价为17.00美元，最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250803000154a6cf783e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250803000154a6cf783e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBNX"],"gpt_icon":0},{"id":"1103250329","title":"异动解读 | Beta Bionics股价盘中大涨10.98%，Truist证券上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1103250329","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103250329?lang=zh_cn&edition=full","pubTime":"2025-07-30 22:46","pubTimestamp":1753886790,"startTime":"0","endTime":"0","summary":"周三盘中，Beta Bionics股价大幅上涨10.98%，引起投资者广泛关注。推动Beta Bionics股价上涨的主要因素是华尔街分析师的积极评价。据悉，Truist Securities分析师于当日将Beta Bionics的目标价从18美元上调至21美元，这一举动显著提振了投资者信心。分析人士认为，Truist Securities上调目标价反映了对Beta Bionics公司未来发展前景的看好。作为一家专注于开发人工胰腺系统的医疗科技公司，Beta Bionics在糖尿病管理领域具有创新优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BBNX"],"gpt_icon":0},{"id":"1100799004","title":"异动解读 | 业绩超预期，Beta Bionics盘后大涨6.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100799004","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100799004?lang=zh_cn&edition=full","pubTime":"2025-07-30 05:06","pubTimestamp":1753823186,"startTime":"0","endTime":"0","summary":"周二盘后，Beta Bionics, Inc.股价大涨6.07%，主要受益于公司发布的季度业绩报告好于市场预期。根据公司公布的财报，截至6月30日的季度调整后每股亏损为39美分，优于分析师平均预期的45美分亏损。值得注意的是，尽管Beta Bionics股价在本季度下跌了3.9%，但华尔街分析师对公司前景仍保持乐观。目前，分析师对该公司股票的平均评级为\"买入\"，12个月目标价中位数为26.00美元，较最新收盘价13.99美元高出约46.2%。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BBNX"],"gpt_icon":0},{"id":"2513777845","title":"Beta Bionics(BBNX.US)获Stifel首次覆盖，给予买入评级, 目标价25.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513777845","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513777845?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:21","pubTimestamp":1740410466,"startTime":"0","endTime":"0","summary":"Beta Bionics(BBNX.US)获Stifel首次覆盖，给予买入评级, 目标价25.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24232148353170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BBNX"],"gpt_icon":0},{"id":"2513722329","title":"Beta Bionics(BBNX.US)获Lake Street首次覆盖，给予买入评级, 目标价30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513722329","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513722329?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:22","pubTimestamp":1740406925,"startTime":"0","endTime":"0","summary":"Beta Bionics(BBNX.US)获Lake Street首次覆盖，给予买入评级, 目标价30.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24222248352806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BBNX"],"gpt_icon":0},{"id":"2513272995","title":"Beta Bionics(BBNX.US)获Piper Sandler首次覆盖，给予增持评级, 目标价26.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513272995","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513272995?lang=zh_cn&edition=full","pubTime":"2025-02-24 21:21","pubTimestamp":1740403316,"startTime":"0","endTime":"0","summary":"Beta Bionics(BBNX.US)获Piper Sandler首次覆盖，给予增持评级, 目标价26.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24212148352460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BBNX"],"gpt_icon":0},{"id":"2513723151","title":"Beta Bionics(BBNX.US)获Leerink Partners首次覆盖，给予优于大市评级, 目标价28.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513723151","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513723151?lang=zh_cn&edition=full","pubTime":"2025-02-24 20:20","pubTimestamp":1740399654,"startTime":"0","endTime":"0","summary":"Beta Bionics(BBNX.US)获Leerink Partners首次覆盖，给予优于大市评级, 目标价28.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24202048351403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BBNX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.betabionics.com","stockEarnings":[{"period":"1week","weight":-0.45},{"period":"1month","weight":-0.4197},{"period":"3month","weight":-0.1827},{"period":"6month","weight":0.3118},{"period":"1year","weight":0.0159},{"period":"ytd","weight":-0.4332}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.1933},{"period":"ytd","weight":0.0174}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Beta Bionics, Inc.于2015年10月21日作为马萨诸塞州福利公司注册成立，并于2024年8月转换为特拉华州公司。公司是一家商业化阶段的医疗器械公司，从事创新解决方案的设计、开发和商业化，通过利用先进的自适应闭环算法简化和改善其疾病的治疗，提高胰岛素需求糖尿病患者的健康和生活质量。","exchange":"NASDAQ","name":"Beta Bionics, Inc.","nameEN":"Beta Bionics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Beta Bionics, Inc.(BBNX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Beta Bionics, Inc.(BBNX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Beta Bionics, Inc.,BBNX,Beta Bionics, Inc.股票,Beta Bionics, Inc.股票老虎,Beta Bionics, Inc.股票老虎国际,Beta Bionics, Inc.行情,Beta Bionics, Inc.股票行情,Beta Bionics, Inc.股价,Beta Bionics, Inc.股市,Beta Bionics, Inc.股票价格,Beta Bionics, Inc.股票交易,Beta Bionics, Inc.股票购买,Beta Bionics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Beta Bionics, Inc.(BBNX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Beta Bionics, Inc.(BBNX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}